ClinicalTrials.gg
CompletedNCT00407537CRUCIALUpdated Jan 28, 2021Results posted

Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors

A Phase 4 interventional study of Amlodipine besylate/atorvastatin calcium single pill combination in Hypertension and Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 126 sites in 20 countries. Open to participants aged 35 Years to 79 Years. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,531
Allocation
Randomized
Ages
35 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 34 studies in Hypertension by Viatris Inc. — none open to participants now, none under way, none of them phase 3. Hypertension · Viatris Inc..

Enrollment
2nd of 27
1,531 · median 330
Started
2007
with 4 others
Phase 4
11 of 34
none open now
Registered
21st of 34
by date

Among the 34 studies in Hypertension by Viatris Inc., this one is the 2nd largest by enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2007, is one of 11 in phase 4, and was the 21st registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 34 studies in Hypertension by Viatris Inc. is open now. The open studies under Hypertension, anywhere →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 35 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 34 studies in Hypertension by Viatris Inc. as a file.
02

Study summary

To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors.

03

Conditions studied

  • Hypertension
  • Hypercholesterolemia
04

Who can participate

Ages eligible
35 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hypertension with three additional risks factors (for example: smoking, type 2 diabetes, family history of early heart disease, history of stroke, age over 55 (men) and 65 (women)

Exclusion criteria

Exclusion Criteria:

  • Subjects currently receiving a statin or stopped statin within 6 months prior to enrollment.
  • Subjects with a history of myocardial infarction and subjects with coronary bypass graft or intra-coronary interventions.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,531 participants (actual)

Study arms

  • Experimental
    Caduet

    Open label caduet added to usual care regimen followed by investigators.

    Drug: Amlodipine besylate/atorvastatin calcium single pill combination

Interventions

  • DrugAmlodipine besylate/atorvastatin calcium single pill combination

    Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion

06

What researchers measure

Primary outcomes

  1. Framingham 10-year Risk of Total Coronary Heart Disease (CHD) at Month 12

    Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated at the end of study treatment (Month 12).

    Time frame: Baseline, Month 12

Secondary outcomes

  1. Framingham 10-year Risk of Total CHD at Month 4

    Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated after 4 months of treatment (Month 4).

    Time frame: Baseline, Month 4

  2. European Systematic COronary Risk Evaluation (SCORE) 10-year Risk of Fatal Cardiovascular Disease (CVD) at Month 12

    European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 12 months of study treatment (Month 12).

    Time frame: Baseline, Month 12

  3. European SCORE 10-year Risk of Fatal CVD at Month 4

    European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 4 months of study treatment (Month 4).

    Time frame: Baseline, Month 4

  4. Framingham 10-year Risk of Stroke at Month 12

    Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific "calibration factor" for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12).

    Time frame: Baseline, Month 12

  5. Framingham 10-year Risk of Stroke at Month 4

    Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific "calibration factor" for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12).

    Time frame: Baseline, Month 4

  6. Change From Baseline in Framingham 10-year Risk of Developing Total CHD

    Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. Change from baseline calculated as mean at observation minus mean at Baseline.

    Time frame: Baseline, Month 4, Month 12

  7. Change From Baseline European SCORE 10-year Risk of Developing Fatal CVD

    European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. Change from baseline calculated as mean at observation minus mean at Baseline.

    Time frame: Baseline, Month 4, Month 12

  8. Mean Systolic and Diastolic Blood Pressure at Month 4

    Time frame: Month 4

  9. Mean Systolic and Diastolic Blood Pressure at Month 12

    Time frame: Month 12

  10. Change From Baseline in Systolic Blood Pressure (SBP) at Month 4

    Time frame: Baseline, Month 4

  11. Change From Baseline in Diastolic Blood Pressure (DBP) at Month 4

    Time frame: Baseline, Month 4

  12. Change From Baseline in SBP at Month 12

    Time frame: Baseline, Month 12

  13. Change From Baseline in DBP at Month 12

    Time frame: Baseline, Month 12

  14. Mean Lipid Parameters at Month 4

    Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.

    Time frame: Month 4

  15. Mean Lipid Parameters at Month 12

    Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.

    Time frame: Month 12

  16. Change From Baseline in Lipid Parameters at Month 4

    Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. Change from baseline measured as mean at Month 4 minus mean at Baseline.

    Time frame: Baseline, Month 4

  17. Change From Baseline in Lipid Parameters at Month 12

    Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.

    Time frame: Baseline, Month 12

  18. Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for Blood Pressure at 4 and 12 Months

    Goals set at \<140/90 mmHg according to the seventh Joint National Committee (JNC) on prevention, detection, evaluation, and treatment of high blood pressure and \<140/90 mm Hg or \<130/80 mm Hg for diabetics ccording to the European Society of Cardiology (ESC) guidelines.

    Time frame: Month 4, Month 12

  19. Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for LDL at 4 and 12 Months

    Goal set at \<100 mg/dL according to the United States (US) National Cholesterol Education Program Adult Treatment Panel 3 and at \<80 mg/dL according to the European (EU) Society of Cardiology guidelines.

    Time frame: Month 4, Month 12

  20. Number of Participants With Lipid and Antihypertensive Treatments Used at 4 and 12 Months

    Treatments indicative of prescribed medications other than study provided Caduet.

    Time frame: Month 4, Month 12

  21. Number of Participants With Increase of Treatment Dosages After 4 Months.

    Treatments indicative of prescribed medications other than study provided Caduet.

    Time frame: Month 4

07

Results

Posted Nov 11, 2011

Participant flow

This was a cluster randomized study: the unit of randomization was the investigator, ie, participants were screened before the investigator was randomized. A total of 136 sites were cluster randomized.

Participant flow — Overall Study
MilestoneCaduetUsual Care
Started779682
Eligible for efficacy analysis760657
Completed686638
Not completed9344
Withdrew: Death52
Withdrew: Adverse event360
Withdrew: Lost to follow-up1219
Withdrew: Other67
Withdrew: Withdrawal by subject3416

Outcome measures

PrimaryFramingham 10-year Risk of Total Coronary Heart Disease (CHD) at Month 12

Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated at the end of study treatment (Month 12).

Time frame:
Baseline, Month 12
Reported as:
Mean · percent risk
Framingham 10-year Risk of Total Coronary Heart Disease (CHD) at Month 12
percent riskCaduetUsual Care
Framingham 10-year Risk of Total Coronary Heart Disease (CHD) at Month 1212.5 ± 8.2616.3 ± 10.51
Statistical analysis
  • Caduet vs Usual Care · Mixed-effect linear model · p = <0.001 (Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Lsmean difference: -4.72 · 95% CI -5.55 to -3.89Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.
SecondaryFramingham 10-year Risk of Total CHD at Month 4

Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated after 4 months of treatment (Month 4).

Time frame:
Baseline, Month 4
Reported as:
Mean · percent risk
Framingham 10-year Risk of Total CHD at Month 4
percent riskCaduetUsual Care
Framingham 10-year Risk of Total CHD at Month 412.5 ± 7.9616.3 ± 10.80
Statistical analysis
  • Caduet vs Usual Care · Mixed-effect linear model · p = <0.001 (Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Lsmean difference: -4.76 · 95% CI -5.58 to -3.93Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.
SecondaryEuropean Systematic COronary Risk Evaluation (SCORE) 10-year Risk of Fatal Cardiovascular Disease (CVD) at Month 12

European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 12 months of study treatment (Month 12).

Time frame:
Baseline, Month 12
Reported as:
Mean · percent risk
European Systematic COronary Risk Evaluation (SCORE) 10-year Risk of Fatal Cardiovascular Disease (CVD) at Month 12
percent riskCaduetUsual Care
European Systematic COronary Risk Evaluation (SCORE) 10-year Risk of Fatal Cardiovascular Disease (CVD) at Month 123.0 ± 2.893.7 ± 3.69
Statistical analysis
  • Caduet vs Usual Care · Mixed-effect linear model · p = <0.001 (Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Lsmean difference: -0.97 · 95% CI -1.23 to -0.72Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.
SecondaryEuropean SCORE 10-year Risk of Fatal CVD at Month 4

European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 4 months of study treatment (Month 4).

Time frame:
Baseline, Month 4
Reported as:
Mean · percent risk
European SCORE 10-year Risk of Fatal CVD at Month 4
percent riskCaduetUsual Care
European SCORE 10-year Risk of Fatal CVD at Month 43.1 ± 3.133.7 ± 3.69
Statistical analysis
  • Caduet vs Usual Care · Mixed-effect linear model · p = <0.001 (Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Lsmean difference: -0.88 · 95% CI -1.16 to -0.59Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.
SecondaryFramingham 10-year Risk of Stroke at Month 12

Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific "calibration factor" for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12).

Time frame:
Baseline, Month 12
Reported as:
Mean · percent risk
Framingham 10-year Risk of Stroke at Month 12
percent riskCaduetUsual Care
Framingham 10-year Risk of Stroke at Month 123.7 ± 2.254.9 ± 2.87
Statistical analysis
  • Caduet vs Usual Care · Mixed-effect linear model · p = <0.001 (Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Lsmean difference: -1.35 · 95% CI -1.56 to -1.15Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.
SecondaryFramingham 10-year Risk of Stroke at Month 4

Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific "calibration factor" for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12).

Time frame:
Baseline, Month 4
Reported as:
Mean · percent risk
Framingham 10-year Risk of Stroke at Month 4
percent riskCaduetUsual Care
Framingham 10-year Risk of Stroke at Month 43.7 ± 2.214.9 ± 2.81
Statistical analysis
  • Caduet vs Usual Care · Mixed-effect linear model · p = <0.001 (Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Lsmean difference: -1.35 · 95% CI -1.57 to -1.14Value at a given visit as response. Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.
SecondaryChange From Baseline in Framingham 10-year Risk of Developing Total CHD

Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. Change from baseline calculated as mean at observation minus mean at Baseline.

Time frame:
Baseline, Month 4, Month 12
Reported as:
Least squares mean · percent risk
Change From Baseline in Framingham 10-year Risk of Developing Total CHD
percent riskCaduetUsual Care
Month 4-7.2705 (-7.90 to -6.64)-2.5155 (-3.19 to -1.84)
Month 12-7.2374 (-7.87 to -6.61)-2.5167 (-3.19 to -1.84)
SecondaryChange From Baseline European SCORE 10-year Risk of Developing Fatal CVD

European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. Change from baseline calculated as mean at observation minus mean at Baseline.

Time frame:
Baseline, Month 4, Month 12
Reported as:
Least squares mean · percent risk
Change From Baseline European SCORE 10-year Risk of Developing Fatal CVD
percent riskCaduetUsual Care
Month 4-1.8438 (-2.06 to -1.63)-0.9678 (-1.20 to -0.74)
Month 12-1.9693 (-2.16 to -1.77)-0.9963 (-1.21 to -0.79)
SecondaryMean Systolic and Diastolic Blood Pressure at Month 4
Time frame:
Month 4
Reported as:
Mean · mmHg
Mean Systolic and Diastolic Blood Pressure at Month 4
mmHgCaduetUsual Care
Systolic133.5 ± 14.32134.5 ± 14.96
Diastolic80.7 ± 8.7481.1 ± 9.32
SecondaryMean Systolic and Diastolic Blood Pressure at Month 12
Time frame:
Month 12
Reported as:
Mean · mmHg
Mean Systolic and Diastolic Blood Pressure at Month 12
mmHgCaduetUsual Care
Systolic130.6 ± 13.84134.3 ± 15.21
Diastolic79.2 ± 8.3981.1 ± 9.27
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) at Month 4
Time frame:
Baseline, Month 4
Reported as:
Least squares mean · mmHG
Change From Baseline in Systolic Blood Pressure (SBP) at Month 4
mmHGCaduetUsual Care
Change From Baseline in Systolic Blood Pressure (SBP) at Month 4-15.3088 (-17.02 to -13.60)-12.1619 (-14.00 to -10.32)
Statistical analysis
  • Caduet vs Usual Care · Mixed-effect linear model · p = <0.007 · Mean difference (final values): -3.15 · 95% CI -5.42 to -0.88
SecondaryChange From Baseline in Diastolic Blood Pressure (DBP) at Month 4
Time frame:
Baseline, Month 4
Reported as:
Least squares mean · mmHG
Change From Baseline in Diastolic Blood Pressure (DBP) at Month 4
mmHGCaduetUsual Care
Change From Baseline in Diastolic Blood Pressure (DBP) at Month 4-8.3024 (-9.24 to -7.36)-6.6908 (-7.70 to -5.68)
Statistical analysis
  • Caduet vs Usual Care · Mixed-effect linear model · p = <0.011 · Mean difference (final values): -1.61 · 95% CI -2.86 to -0.37
SecondaryChange From Baseline in SBP at Month 12
Time frame:
Baseline, Month 12
Reported as:
Least squares mean · mmHg
Change From Baseline in SBP at Month 12
mmHgCaduetUsual Care
Change From Baseline in SBP at Month 12-18.2409 (-19.94 to -16.55)-12.4903 (-14.32 to -10.66)
Statistical analysis
  • Caduet vs Usual Care · Mixed-effect linear model · p = <0.001 · Mean difference (final values): -5.75 · 95% CI -8.00 to -3.50
SecondaryChange From Baseline in DBP at Month 12
Time frame:
Baseline, Month 12
Reported as:
Least squares mean · mmHg
Change From Baseline in DBP at Month 12
mmHgCaduetUsual Care
Change From Baseline in DBP at Month 12-10.0128 (-10.96 to -9.07)-6.8429 (-7.86 to -5.83)
Statistical analysis
  • Caduet vs Usual Care · Mixed-effect linear model · p = <0.001 · Mean difference (final values): -3.17 · 95% CI -4.42 to -1.92
SecondaryMean Lipid Parameters at Month 4

Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.

Time frame:
Month 4
Reported as:
Mean · mg/dL
Mean Lipid Parameters at Month 4
mg/dLCaduetUsual Care
TC156.0 ± 34.14195.2 ± 37.03
LDL80.9 ± 28.47116.4 ± 32.47
HDL47.6 ± 13.9346.8 ± 13.49
Triglycerides143.5 ± 83.26164.8 ± 95.74
Statistical analysis
  • Caduet vs Usual Care · Mixed-effect linear model · p = <0.001 (Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Mean difference (final values): -38.94 · 95% CI -43.71 to -34.17
  • Caduet vs Usual Care · Mixed-effect linear model · p = <0.001 (Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Mean difference (final values): -35.31 · 95% CI -39.64 to -30.99
  • Caduet vs Usual Care · Mixed-effect linear model · p = 0.087 (Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Mean difference (final values): 0.99 · 95% CI -0.14 to 2.13
  • Caduet vs Usual Care · Mixed-effects linear model · p = <0.001 (Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Mean difference (final values): -23.65 · 95% CI -32.60 to -14.70
SecondaryMean Lipid Parameters at Month 12

Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.

Time frame:
Month 12
Reported as:
Mean · mg/dL
Mean Lipid Parameters at Month 12
mg/dLCaduetUsual Care
TC163.3 ± 38.42196.6 ± 36.36
LDL87.1 ± 32.40117.3 ± 31.57
HDL47.3 ± 13.4847.1 ± 13.61
Triglycerides151.5 ± 98.61166.4 ± 98.53
Statistical analysis
  • Caduet vs Usual Care · Mixed-effect linear model · p = <0.001 (Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Mean difference (final values): -33.07 · 95% CI -37.57 to -28.56
  • Caduet vs Usual Care · Mixed-effect linear model · p = <0.001 (Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Mean difference (final values): -29.83 · 95% CI -33.70 to -25.95
  • Caduet vs Usual Care · Mixed-effect linear model · p = 0.379 (Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Mean difference (final values): 0.58 · 95% CI -0.71 to 1.86
  • Caduet vs Usual Care · Mixed-effect linear model · p = <0.001 (Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Mean difference (final values): -18.27 · 95% CI -28.72 to -7.81
SecondaryChange From Baseline in Lipid Parameters at Month 4

Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. Change from baseline measured as mean at Month 4 minus mean at Baseline.

Time frame:
Baseline, Month 4
Reported as:
Least squares mean · mg/dL
Change From Baseline in Lipid Parameters at Month 4
mg/dLCaduetUsual Care
TC-42.7542 (-46.35 to -39.15)-3.8144 (-7.75 to 0.12)
LDL-38.2765 (-41.52 to -35.03)-2.9628 (-6.50 to 0.58)
HDL-0.2060 (-1.07 to 0.65)-1.1978 (-2.13 to -0.26)
Triglycerides-20.5645 (-27.30 to -13.83)3.0828 (-4.26 to 10.43)
Statistical analysis
  • Caduet vs Usual Care · Mixed-effect linear model · p = <0.001 (Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Mean difference (final values): -38.94 · 95% CI -43.71 to -34.17
  • Caduet vs Usual Care · Mixed-effect linear model · p = <0.001 (Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Mean difference (final values): -35.31 · 95% CI -39.64 to -30.99
  • Caduet vs Usual Care · mixed-effect linear model · p = 0.087 (Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Mean difference (final values): 0.99 · 95% CI -0.14 to 2.13
  • Caduet vs Usual Care · Mixed-effect linear model · p = <0.001 (Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Mean difference (final values): -23.65 · 95% CI -32.60 to -14.70
SecondaryChange From Baseline in Lipid Parameters at Month 12

Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · mg/dL
Change From Baseline in Lipid Parameters at Month 12
mg/dLCaduetUsual Care
TC-37.1024 (-40.52 to -33.69)-4.0368 (-7.71 to -0.36)
LDL-33.2420 (-36.17 to -30.32)-3.4168 (-6.58 to -0.25)
HDL-0.4339 (-1.41 to 0.54)-1.0105 (-2.06 to 0.04)
Triglycerides-15.2270 (-23.12 to -7.33)3.0398 (-5.51 to 11.59)
Statistical analysis
  • Caduet vs Usual Care · Mixed-effect linear model · p = <0.001 (Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Mean difference (final values): -33.07 · 95% CI -37.57 to -28.56
  • Caduet vs Usual Care · Mixed-effect linear model · p = <0.001 (Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Mean difference (final values): -29.83 · 95% CI -33.70 to -25.95
  • Caduet vs Usual Care · mixed-effect linear model · p = 0.379 (Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Mean difference (final values): 0.58 · 95% CI -0.71 to 1.86
  • Caduet vs Usual Care · Mixed-effect linear model · p = <0.001 (Baseline value, country, and treatment were used as fixed effect and site was used as a random effect and a compound-symmetry (CS) variance-covariance matrix was used for subjects from the same site.) · Mean difference (final values): -18.27 · 95% CI -28.72 to -7.81
SecondaryPercentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for Blood Pressure at 4 and 12 Months

Goals set at \<140/90 mmHg according to the seventh Joint National Committee (JNC) on prevention, detection, evaluation, and treatment of high blood pressure and \<140/90 mm Hg or \<130/80 mm Hg for diabetics ccording to the European Society of Cardiology (ESC) guidelines.

Time frame:
Month 4, Month 12
Reported as:
Number · percentage of participants
Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for Blood Pressure at 4 and 12 Months
percentage of participantsCaduetUsual Care
JNC Month 465.262.6
JNC Month 1276.160.6
ESC Month 448.646.0
ESC Month 1258.247.5
SecondaryPercentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for LDL at 4 and 12 Months

Goal set at \<100 mg/dL according to the United States (US) National Cholesterol Education Program Adult Treatment Panel 3 and at \<80 mg/dL according to the European (EU) Society of Cardiology guidelines.

Time frame:
Month 4, Month 12
Reported as:
Number · Percentage of participants
Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for LDL at 4 and 12 Months
Percentage of participantsCaduetUsual Care
US Month 477.328.2
US Month 1271.928.8
EU Month 452.413.3
EU Month 1246.711.5
SecondaryNumber of Participants With Lipid and Antihypertensive Treatments Used at 4 and 12 Months

Treatments indicative of prescribed medications other than study provided Caduet.

Time frame:
Month 4, Month 12
Reported as:
Number · participants
Number of Participants With Lipid and Antihypertensive Treatments Used at 4 and 12 Months
participantsCaduetUsual Care
Month 4: anti-hypertensive and/or lipid lowering648642
Month 4: anti-hypertensive647637
Month 4: lipid lowering45202
Month 4: anti-hypertensive and lipid lowering44197
Month 12: anti-hypertensive and/or lipid lowering655642
Month 12: anti-hypertensive654638
Month 12: lipid lowering46208
Month 12: anti-hypertensive and lipid lowering45204
SecondaryNumber of Participants With Increase of Treatment Dosages After 4 Months.

Treatments indicative of prescribed medications other than study provided Caduet.

Time frame:
Month 4
Reported as:
Number · Participants
Number of Participants With Increase of Treatment Dosages After 4 Months.
ParticipantsCaduetUsual Care
Increased dose3090
increased dose of anti-hypertensive medications3088
increased dose of lipid lowering medications02
increase in either medication445
increase in both medications00

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Caduet—51/779 (6.5%)356/779 (45.7%)
Usual Care—22/682 (3.2%)289/682 (42.4%)
Most frequent serious events
Showing 10 of 80
Most frequent serious events
EventCaduetUsual Care
Urinary tract infectionInfections and infestations3/7790/682
Acute myocardial infarctionCardiac disorders2/7792/682
Myocardial ischaemiaCardiac disorders0/7792/682
Myocardial infarctionCardiac disorders2/7790/682
Chest painGeneral disorders2/7790/682
AppendicitisInfections and infestations2/7791/682
PneumoniaInfections and infestations2/7790/682
HyperglycaemiaMetabolism and nutrition disorders2/7790/682
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/7790/682
Ischaemic strokeNervous system disorders2/7790/682
Most frequent other events
Showing 10 of 363
Most frequent other events
EventCaduetUsual Care
Oedema peripheralGeneral disorders52/77911/682
HeadacheNervous system disorders23/77915/682
NasopharyngitisInfections and infestations22/77910/682
BronchitisInfections and infestations12/77915/682
DizzinessNervous system disorders17/7799/682
Chest painGeneral disorders16/77910/682
Upper respiratory tract infectionInfections and infestations16/77914/682
Blood triglycerides increasedInvestigations11/77914/682
Blood creatine phosphokinase increasedInvestigations15/7795/682
PharyngitisInfections and infestations6/77913/682

Baseline characteristics

Age, Customized
Age, Customized(participants)Caduet as AssignedUsual Care as AssignedTotal
< 18 years000
18 to 44 years5855113
45 to 64 years450361811
> = 65 years275262537
Sex: Female, Male
Sex: Female, Male(Participants)Caduet as AssignedUsual Care as AssignedTotal
Female368334702
Male415344759
08

Study locations

126 sites
  • Pfizer Investigational Site
    Desamparados, San Jose, Costa Rica
  • Pfizer Investigational Site
    Heredia, Costa Rica
  • Pfizer Investigational Site
    San Jose, Costa Rica
  • Pfizer Investigational Site
    Breznicki Hum, 42225, Croatia
  • Pfizer Investigational Site
    Cakovec, 40000, Croatia
  • Pfizer Investigational Site
    Crikvenica, 51260, Croatia
  • Pfizer Investigational Site
    Karlovac, 47000, Croatia
  • Pfizer Investigational Site
    Rijeka, 51000, Croatia
  • Pfizer Investigational Site
    Spisic Bukovica, 33404, Croatia
  • Pfizer Investigational Site
    Split, 21000, Croatia
  • Pfizer Investigational Site
    Sv. Kriz Zacretje, 49223, Croatia
  • Pfizer Investigational Site
    Varazdin, 42000, Croatia
  • Pfizer Investigational Site
    Zagreb, 10000, Croatia
  • Pfizer Investigational Site
    Brno, 656 91, Czechia
  • Pfizer Investigational Site
    Klatovy, 339 01, Czechia
  • Pfizer Investigational Site
    Kralupy nad Vltavou, 278 01, Czechia
  • Pfizer Investigational Site
    Lanskroun, 563 01, Czechia
  • Pfizer Investigational Site
    Olomouc, 779 00, Czechia
  • Pfizer Investigational Site
    Pelhrimov, 393 01, Czechia
  • Pfizer Investigational Site
    Praha 4, 141 00, Czechia
  • Pfizer Investigational Site
    Praha 8, 186 00, Czechia
  • Pfizer Investigational Site
    Pruhonice, 252 43, Czechia
  • Pfizer Investigational Site
    Usti nad Labem, 400 07, Czechia
  • Pfizer Investigational Site
    Vratimov, 739 32, Czechia
  • Pfizer Investigational Site
    Zlin 4, 763 02, Czechia
  • Pfizer Investigational Site
    San Cristobal, Dominican Republic
  • Pfizer Investigational Site
    Santo Domingo, 4966, Dominican Republic
  • Pfizer Investigational Site
    Santo Domingo, Dominican Republic
  • Pfizer Investigational Site
    Cilandak, Jakarta Selatan 12430, Indonesia
  • Pfizer Investigational Site
    Bandung, 40161, Indonesia
  • Pfizer Investigational Site
    Jakarta, 10430, Indonesia
  • Pfizer Investigational Site
    Jakarta, 11420, Indonesia
  • Pfizer Investigational Site
    Semarang, 50231, Indonesia
  • Pfizer Investigational Site
    Surabaya, 60286, Indonesia
  • Pfizer Investigational Site
    Tangerang, 15224, Indonesia
  • Pfizer Investigational Site
    Tanggerang, 15811, Indonesia
  • Pfizer Investigational Site
    Amman, 11181, Jordan
  • Pfizer Investigational Site
    Amman, 11942, Jordan
  • Pfizer Investigational Site
    Irbid, 22110, Jordan
  • Pfizer Investigational Site
    Wonju-si, Gangwon-Do 220-701, Korea, Republic of
  • Pfizer Investigational Site
    Seongnam-si, Gyeonggi-do 463-707, Korea, Republic of
  • Pfizer Investigational Site
    Busan, 602-715, Korea, Republic of
  • Pfizer Investigational Site
    Busan, 614-735, Korea, Republic of
  • Pfizer Investigational Site
    Daegu, 700-712, Korea, Republic of
  • Pfizer Investigational Site
    Daegu, 705-718, Korea, Republic of
  • Pfizer Investigational Site
    Daejeon, 301-721, Korea, Republic of
  • Pfizer Investigational Site
    Gwangju, Korea, Republic of
  • Pfizer Investigational Site
    Incheon, 405-760, Korea, Republic of
  • Pfizer Investigational Site
    Seoul,, 150-713, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 110-744, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 135-710, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 135-720, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 136-705, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 137-040, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 138-736, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 152-703, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, Korea, Republic of
  • Pfizer Investigational Site
    Suwon, 443-721, Korea, Republic of
  • Pfizer Investigational Site
    Kuwait, Kuwait
  • Pfizer Investigational Site
    Sasat, 13110, Kuwait
  • Pfizer Investigational Site
    Beirut, Lebanon
  • Pfizer Investigational Site
    Jbeil, Lebanon
  • Pfizer Investigational Site
    Kuala Pilah, Negeri Sembilan 72000, Malaysia
  • Pfizer Investigational Site
    Seremban, Negeri Sembilan 70300, Malaysia
  • Pfizer Investigational Site
    Batu Caves, Selangor 68100, Malaysia
  • Pfizer Investigational Site
    Petaling Jaya, Selangor 47301, Malaysia
  • Pfizer Investigational Site
    Butterworth, 13000, Malaysia
  • Pfizer Investigational Site
    Kuala Lumpur, 57000, Malaysia
  • Pfizer Investigational Site
    Kuala Lumpur, 59100, Malaysia
  • Pfizer Investigational Site
    Mexico, DF 02720, Mexico
  • Pfizer Investigational Site
    Mexico, DF 07300, Mexico
  • Pfizer Investigational Site
    Mexico, DF 09220, Mexico
  • Pfizer Investigational Site
    Mexico, DF 10700, Mexico
  • Pfizer Investigational Site
    Toluca, Estado De Mexico 50010, Mexico
  • Pfizer Investigational Site
    Guadalajara, Jalisco 44200, Mexico
  • Pfizer Investigational Site
    Guadalajara, Jalisco 44340, Mexico
  • Pfizer Investigational Site
    Durango, 34078, Mexico
  • Pfizer Investigational Site
    San Luis Potosi, 78200, Mexico
  • Pfizer Investigational Site
    Panama City, Panama
  • Pfizer Investigational Site
    Panama, Panama
  • Pfizer Investigational Site
    San Juan, Metro Manila, Philippines
  • Pfizer Investigational Site
    Makati City, 1218, Philippines
  • Pfizer Investigational Site
    Manila, 1000, Philippines
  • Pfizer Investigational Site
    Marikina City, Philippines
  • Pfizer Investigational Site
    Quezon City, 1101, Philippines
  • Pfizer Investigational Site
    Moscow, 101953, Russian Federation
  • Pfizer Investigational Site
    Moscow, 1117292, Russian Federation
  • Pfizer Investigational Site
    Moscow, 115093, Russian Federation
  • Pfizer Investigational Site
    Moscow, 117485, Russian Federation
  • Pfizer Investigational Site
    Saint Petersburg, 199106, Russian Federation
  • Pfizer Investigational Site
    Saint-Petersburg, 192242, Russian Federation
  • Pfizer Investigational Site
    Saint-Petersburg, 196084, Russian Federation
  • Pfizer Investigational Site
    Smolensk, 214018, Russian Federation
  • Pfizer Investigational Site
    St. Petersburg, 190000, Russian Federation
  • Pfizer Investigational Site
    St. Petersburg, 194291, Russian Federation
  • Pfizer Investigational Site
    St. Petersburg, 195067, Russian Federation
  • Pfizer Investigational Site
    Volgograd, 400008, Russian Federation
  • Pfizer Investigational Site
    Voronezh, 394053, Russian Federation
  • Pfizer Investigational Site
    Riyadh 11426, Riyadh 11426, Saudi Arabia
  • Pfizer Investigational Site
    Kaohsiung, 807, Taiwan

Showing the first 100 of 126 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Cho EJ, Kim JH, Sutradhar S, Yunis C, Westergaard M; CRUCIAL Trial Investigators. Proactive multifactorial intervention strategy reduces the risk of cardiovascular disease estimated with region-specific risk assessment models in Pacific Asian patients participating in the CRUCIAL trial. J Korean Med Sci. 2013 Dec;28(12):1741-8. doi: 10.3346/jkms.2013.28.12.1741. Epub 2013 Nov 26. PubMed 24339703 ↗
  • Hradec J, Zamorano J, Sutradhar S. Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial. Curr Med Res Opin. 2013 Jun;29(6):589-96. doi: 10.1185/03007995.2013.783795. Epub 2013 Apr 3. PubMed 23464930 ↗
  • Kim JH, Zamorano J, Erdine S, Pavia A, Al-Khadra A, Sutradhar S, Yunis C; CR UCIAL Investigators. Proactive cardiovascular risk management versus usual care in patients with and without diabetes mellitus: CRUCIAL trial subanalysis. Postgrad Med. 2012 Jul;124(4):41-53. doi: 10.3810/pgm.2012.07.2565. PubMed 22913893 ↗
  • Zamorano J, Erdine S, Pavia A, Kim JH, Al-Khadra A, Westergaard M, Sutradhar S, Yunis C; CRUCIAL Investigators. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr Med Res Opin. 2011 Apr;27(4):821-33. doi: 10.1185/03007995.2011.555754. Epub 2011 Feb 10. PubMed 21306285 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2011, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2006
First posted
Dec 5, 2006
Start
Mar 2007
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
Nov 11, 2011
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00407537
Responsible party
Sponsor
First posted
Dec 5, 2006
Start date
Mar 2007
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Nov 11, 2011
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion